Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 18/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.79 |
| ▸ | KDR | P35968 | 14/20 | 0.79 |
| ▸ | TEK | Q02763 | 4/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | FYN | P06241 | 1/20 | 0.72 |
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
| ▸ | LYN | P07948 | 1/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.72 |
| ▸ | JAK3 | P52333 | 2/20 | 0.69 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944806 | 0.88 | LCK (1.00) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL15642990 | 0.88 | LCK (0.87) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL2943791 | 0.87 | LCK (1.00) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL2951411 | 0.87 | LCK (1.00) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL2942416 | 0.87 | LCK (1.00) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL3099304 | 0.87 | LCK (0.76) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL2948429 | 0.86 | LCK (1.00) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL15127489 | 0.86 | LCK (0.87) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL13154272 | 0.85 | LCK (0.90) | LCKMAPK14KDRTEKABL1 | |
| SCHEMBL15679146 | 0.85 | LCK (0.92) | LCKMAPK14KDRTEKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928844-B1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-04-23 | — | — | EP | claimed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | claimed |
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | claimed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | claimed |
| EP-1928844-B1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-1928844-B1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | LCK, BTK, IRAK1 | LCK 1/4885MAPK14 525/4885KDR 674/4885 |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | LCK 1/4885MAPK14 525/4885KDR 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.